Drugs / MF59 adjuvant

Trials 5 · a red edge is where a trial was stopped

20052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 13 trials
Phase 1 NCT02624219 Aug 2016 → Jan 2018 avian influenza National Institute of Allergy and Infectious Diseases (NIAID) Completed No outcome recorded
Phase 1 NCT02251288 May 2015 → Aug 2018 avian influenza National Institute of Allergy and Infectious Diseases (NIAID) Completed No outcome recorded
Phase 1 NCT01317745 May 2011 → Sep 2012 influenza National Institute of Allergy and Infectious Diseases (NIAID) Completed No outcome recorded
Phase 1/21 trial
Phase 1/2 NCT00133471 Mar → Dec 2005 influenza National Institute of Allergy and Infectious Diseases (NIAID) Completed No outcome recorded
Phase 21 trial
Phase 2 NCT03497845 Mar 2018 → Nov 2019 avian influenza Biomedical Advanced Research and Development Authority Completed No outcome recorded

Evidence & citations 4 cited values

Every value below carries the sentence it was read from. 5 sources stand behind the page.

FieldValueCited text
Known as MF59 adjuvant ClinicalTrials.gov intervention name — accepted as the source's own label NCT02251288
4

NCT00133471

NCT01317745

NCT03497845

NCT02624219

Known as Microfluoridized adjuvant 59 Microfluoridized adjuvant 59 (MF59) is an oil-in-water emulsion.” NCT02624219
Modality Other / unclassified “MF59 adjuvant is an oil-in-water emulsion.” NCT00133471
Route Intramuscular “All injections will be administered in a 0.5-mL volume into the deltoid muscle.” NCT00133471